aTyr Pharma Announces Food and drug administration Orphan Drug Designation for Efzofitimod (ATYR1923) for Remedy of Systemic Sclerosis

aTyr Pharma, Inc.

Next U.S. orphan drug designation for efzofitimod scientific system

SAN DIEGO, April 13, 2022 (World NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: Life), a scientific phase biotherapeutics company engaged in the discovery and growth of modern medicines primarily based on novel organic pathways, nowadays introduced that the U.S. Food and Drug Administration (Fda) has granted the company orphan drug designation for its lead therapeutic candidate, efzofitimod, for the remedy of systemic sclerosis (SSc, also recognised as scleroderma).

Efzofitimod is a likely very first-in-class immunomodulator that downregulates innate and adaptive immune responses in uncontrolled inflammatory disorder states by way of selective modulation of neuropilin-2 (NRP2). Clinical evidence-of-idea was a short while ago recognized for efzofitimod in a Stage 1b/2a examine in individuals with pulmonary sarcoidosis, a important variety of interstitial lung disorder (ILD). Several patients with SSc may well produce associated ILD, acknowledged as SSc-ILD. The pathology of SSc-ILD is pushed by the identical immune cells that are central to sarcoidosis pathology, and NRP2 is upregulated on these cells, particularly on macrophages. Also, efzofitimod has been demonstrated to lessen lung and pores and skin fibrosis in animal versions of SSc and idiopathic pulmonary fibrosis, where by it matched or outperformed known anti-fibrotic brokers, together with nintedanib and pirfenidone.

“We are extremely delighted to obtain orphan drug designation for efzofitimod for SSc, which marks the 2nd these types of designation for our efzofitimod medical system,” mentioned Sanjay S. Shukla, M.D., M.S., President and CEO of aTyr. “The data we have offered in animal designs of SSc along with the favourable results described from our the latest Stage 1b/2a examine in pulmonary sarcoidosis people counsel that efzofitimod has the opportunity to be a new treatment method solution that resolves irritation and subsequent fibrosis in those people residing with SSc-ILD. We glance ahead to checking out the prospective expansion of our efzofitimod clinical software into other types of ILD with substantial unmet need where this novel therapeutic may be equipped to enhance individual results.”

The FDA’s Office environment of Orphan Drug Products grants orphan status to help the development of medicines for clients with unmet requirements for exceptional problems impacting less than 200,000 persons in the United States. Orphan drug designation provides specified positive aspects, which includes the likely for 7 decades of industry exclusivity subsequent regulatory approval, exemption from Fda application costs and tax credits for experienced medical trials.

Systemic sclerosis is a long-term, progressive, autoimmune illness characterised by irritation and fibrosis of connective tissues during the human body, such as the pores and skin and other interior organs. SSc that occurs in the lungs is referred to as SSc-ILD. It is estimated that approximately 100,000 individuals in the U.S. are affected by SSc and 55-65% may establish ILD. SSc-ILD triggers inflammation in the lungs and, if left untreated, can end result in scarring that triggers long lasting loss of lung purpose. ILD is the principal result in of demise in clients with SSc. Present treatment method options for SSc-ILD are minimal, mainly focus on slowing illness development and are involved with sizeable toxicity.

About Efzofitimod

aTyr is establishing efzofitimod as a prospective therapeutic for clients with fibrotic lung illness. Efzofitimod, a fusion protein comprised of the immunomodulatory area of histidyl-tRNA synthetase fused to the FC area of a human antibody, is a selective modulator of neuropilin-2 that downregulates innate and adaptive immune reaction in inflammatory disease states. aTyr’s direct sign for efzofitimod is pulmonary sarcoidosis, a key type of interstitial lung sickness. Clinical evidence-of-concept for efzofitimod was not long ago established in a Period 1b/2a many-ascending dose, placebo-managed examine of efzofitimod in individuals with pulmonary sarcoidosis, which demonstrated basic safety and a steady dose reaction and tendencies of gain of efzofitimod as opposed to placebo on vital efficacy endpoints, which includes steroid reduction, lung functionality, clinical indications and inflammatory biomarkers. aTyr intends to initiate a prepared registrational research of efzofitimod in pulmonary sarcoidosis in the third quarter of 2022.

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines dependent on novel biological pathways. aTyr’s analysis and progress endeavours are concentrated on a recently discovered location of biology, the extracellular performance and signaling pathways of tRNA synthetases. aTyr has constructed a global mental home estate directed to a likely pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s most important emphasis is efzofitimod, a clinical-phase product applicant which binds to the neuropilin-2 receptor and is made to downregulate immune engagement in fibrotic lung illness. For more facts, please take a look at

Forward-Wanting Statements

This press release incorporates forward-searching statements inside of the that means of the Private Securities Litigation Reform Act of 1995. Forward-wanting statements are usually determined by the use of text this kind of as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of these kinds of phrases or similar expressions. We intend these forward-looking statements to be covered by this sort of secure harbor provisions for ahead-looking statements and are creating this statement for applications of complying with those people risk-free harbor provisions. These ahead-searching statements include statements pertaining to the possible of efzofitimod to be a new remedy alternative that resolves swelling and subsequent fibrosis in those people residing with SSc-ILD, the potential expansion of our efzofitimod scientific software into other kinds of ILD with high unmet have to have, the potential of efzofitimod to increase affected individual outcomes, prospective added benefits of orphan drug designation, and the timing of our planned registrational study of efzofitimod in pulmonary sarcoidosis. These forward-on the lookout statements also replicate our recent sights about our options, intentions, expectations, strategies and potential customers, which are based on the information and facts at this time offered to us and on assumptions we have manufactured. Although we believe that that our ideas, intentions, anticipations, strategies and prospective buyers, as mirrored in or suggested by these forward-searching statements, are sensible, we can give no assurance that the ideas, intentions, expectations or procedures will be attained or reached. All ahead-on the lookout statements are based on estimates and assumptions by our management that, whilst we believe to be acceptable, are inherently unsure. On top of that, real effects may well vary materially from all those described in these ahead-wanting statements and will be impacted by a variety of challenges and elements that are outside of our control which include, with out limitation, uncertainty concerning the COVID-19 pandemic, pitfalls involved with the discovery, growth and regulation of our item candidates, the hazard that we or our associates might stop or hold off preclinical or clinical growth actions for any of our current or long term products candidates for a wide variety of factors (together with difficulties or delays in patient enrollment in prepared medical trials), the risk that current collaborations could be terminated early, and the danger that we may not be able to elevate the extra funding needed for our business and product or service advancement plans, as perfectly as people pitfalls established forth in our Annual Report on Type 10-K for the year finished December 31, 2021 submitted with the Securities and Exchange Commission on March 15, 2022 and in our other SEC filings. Besides as necessary by legislation, we presume no obligation to update publicly any ahead-on the lookout statements, regardless of whether as a end result of new info, foreseeable future activities or otherwise.

Ashlee Dunston
Director, Investor Relations and Company Communications
[email protected]